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Abstract
Background The increased value of the red cell distri-
bution width (RDW) was reported to indicate poor prog-
nosis in patients with chronic heart failure. We evaluated
the value of the RDW in the diagnosis of left ventricular
diastolic dysfunction (LVDD) in patients without diastolic
heart failure among the chronic kidney disease (CKD)
population.
Methods The study group consisted of 73 ambulatory
patients with CKD, stages 2–5. Standard echocardiography
and tissue Doppler imaging (TDI) were performed, and the
level of RDW was determined. Patients were divided into
four groups according to the results of peak early diastolic
velocity of mitral annulus (EmLV) and the stage of CKD:
group with early stage CKD (eGFR[ 30 ml/min/1.73 m2)
without LVDD (EmLV C 8 cm/s), early stage CKD with
LVDD (EmLV\ 8 cm/s), group with advanced stage
CKD (eGFR B 30 ml/min/1.73 m2) without LVDD, and
group with advanced stage CKD with LVDD.
Results Patients with advanced stage CKD with LVDD
were characterized by higher RDW levels than patients
with advanced stage CKD without LVDD and with early
stage CKD groups with and without LVDD [14.5
(13.8–19.5) % vs. 13.7 (11.4–15,4) %, p = 0.049, vs.
13.8(13.1–14.9) %, p = 0.031, vs. 13.7(12.1–16.2) %,
p = 0.0007], respectively. The area under the receiver
operating characteristic (ROC) curve of RDW level for the
detection of LVDD was 0.649, 95 % confidence interval
(CI) 0.528–0.758, p = 0.021, whereas ROC derived RDW
value of [13.5 % was characterized by a sensitivity of
83.3 % and specificity of 45.2 % for predicting LVDD.
The only independent factor of LVDD was RDW level
[13.5 % with odds ratio (OR) = 3.92 (95 % CI
1.05–14.56), p = 0.037.
Conclusion RDW can be used as an additional factor for
the diagnosis of LVDD in patients with advanced stage of
CKD.
Keywords RDW  Chronic kidney disease  Left
ventricular diastolic dysfunction
Introduction
Red cell distribution width (RDW) is a measurement of the
size variability of the red blood cell population. It is
assessed by standard blood count usually automatically,
and is widely available [1]. Generally, a high RDW level
may reflect reticulocytosis, hemolytic disorders [2]. It has
also known that RDW levels are elevated in inflammatory
bowel diseases, pregnancy, liver and kidney diseases, and
during inflammatory processes [3–5]. Recently, the
increased value of the RDW was reported to indicate poor
prognosis in patients with chronic heart failure, coronary
artery disease, and pulmonary hypertension [6–11]. It has
also shown that the RDW is associated with endothelial
dysfunction in patients with chronic kidney disease (CKD)
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[12]. This interest was spurred by the report from Celik A
et al. [13] which showed that there is a strong, independent
association between RDW and elevated left ventricular
filling pressure (LVFP) among patients with diastolic heart
failure (DHF). In the current study, we evaluated the value
of the RDW in the diagnosis of left ventricular diastolic
dysfunction (LVDD) in patients without DHF among the
CKD population.
Patients and methods
The study group consisted of 73 ambulatory patients with
CKD, stages 2–5, with preserved LV systolic function
defined by left ventricular ejection fraction (LVEF)[50 %
and with sinus rhythm. Exclusion criteria comprised: non-
sinus rhythm, LV systolic dysfunction, previous myocar-
dial infarction, cardiomyopathy, severe valvular heart dis-
ease, pericardial fluid, active chronic inflammation, or
acute infectious diseases within 4 weeks. Diagnostic cri-
teria for CKD were consistent with the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI) standards [14].
Echocardiography
Standard echocardiography was performed for all patients
using a GE 6S device with 2.5–3.5 MHz transducer. To
increase the credibility of the obtained echocardiographic
results, the physician who performed the examination was
unaware of the biochemical parameters of the patients. The
examinations were conducted in stable patients and par-
ticular attention was placed on retaining optimal hydration.
Using the M-MODE in the parasternal long-axis view
the following parameters were measured: left ventricular
end-diastolic dimension (LVEDD), right ventricular end-
diastolic dimension (RVEDD), left atrial diastolic dimen-
sion (LAD), interventricular septal diastolic diameter (IV-
SDd), and left ventricular LV posterior wall dimension at
diastole (LVPWd). In a four chamber view, left ventricular
ejection fraction (LVEF) was measured by modified
Simpson’s method [15]. Left ventricular mass (LVM) was
calculated by the formula described by Devereux et al., and
left ventricular mass index (LVMI) was obtained by
dividing the left ventricular mass by the body surface area
[16]. To assess transmitral flow, pulsed wave Doppler
echocardiography was performed in a four chamber view.
The Doppler gate was placed at the tips of the mitral valve
leaflets and a two-phase flow profile was obtained,
including: early (E) and late (A) transmitral velocities,
deceleration time (DT) of the E wave, E/A ratio was also
calculated [15].
Tissue Doppler echocardiography
Tissue Doppler parameters were measured: peak mitral
annular systolic velocity (SmLV), peak early diastolic
velocity (EmLV), and peak late diastolic velocity (AmLV)
[17]. These parameters were obtained from the apical four
chamber view. In pulsed wave tissue Doppler echocardi-
ography, diastolic and systolic velocities were measured by
placing the Doppler gate on the lateral mitral annulus at the
posterior leaflet of the mitral valve. The ratio of peak early
transmitral velocity to peak early diastolic velocity (E/Em)
was calculated for the lateral annulus. All parameters were
calculated as the mean of measurements taken in three
consecutive cardiac cycles. LVDD was defined as EmLV
\ 8 cm/s [18].
Biochemical tests
On the day of echocardiographic examination, the fol-
lowing laboratory parameters were measured for patients:
serum creatinine concentration, eGFR evaluated by the
modified MDRD formula, as well as the serum levels of
urea, parathormone (PTH), C-reactive protein (CRP),
serum levels of albumin, and NT-proBNP levels were
calculated by immunoassay with the Stratus R CS Acute
Care TM Siemens.
Additionally, blood samples were taken and following
parameters were recorded: hemoglobin concentration (Hb),
hematocrit (Ht), mean corpuscular volume (MCV), plate-
lets (PLT), red blood cells (RBC), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin con-
centration (MCHC), red cell distribution width (RDW),
mean platelet volume (MPV), platelet distribution width
(PDW), plateletcrit (PCT), and platelet-large cell ratio (P-
LCR).
Patients were divided into four groups depending on the
results of eGFR level. Group 1 (eGFR 89–60 ml/min/
1.73 m2), Group 2 (eGFR 59–30 ml/min/1.73 m2), Group
3 (eGFR 29–15 ml/min/1.73 m2), and Group 4
(eGFR\ 15 ml/min/1.73 m2). Subsequently all patients
were divided into another four groups according to the
results of EmLV and the stage of CKD: early stage CKD
(eGFR[ 30 ml/min/1.73 m2) without LVDD
(EmLV C 8 cm/s), early stage CKD with LVDD
(EmLV\ 8 cm/s), advanced stage CKD (eGFR B 30 ml/
min/1.73 m2) without LVDD, and advanced stage CKD
with LVDD.
Statistical analysis
Values of parameters with a normal distribution were
presented as a mean ± SD, whereas values with non-nor-
mal distributions were expressed as median and range. To
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compare four groups, analysis of variance (ANOVA) was
used. Pearson’s or Spearmans’s correlation tests were used
for correlation between variables. A receiver operating
characteristic (ROC) analysis curves served to determine
the optimal cut-off point of RDW and NT-proBNP for
identifying patients with LVDD. Areas under the curve
were calculated as measures of the accuracy of the tests.
Multivariate logistic regression analysis was used to
determine which factors are independently associated with
EmLV\ 8 cm/s. To assess the diagnostic value, odds ratio
for particular laboratory and echocardiographic parameters
was calculated. In the analysis, the parameters were treated
either continuously or dichotomously using their values as
determined in the ROC analysis. A value of p\ 0.05 was
considered statistically significant.
Ethics approval
All patients consented in writing for the inclusion in the
research. The study protocol was approved by the Bioethics
Committee (no 555/2011).
Results
The current study included 73 patients with CKD in stages
2–5 (28 male and 45 female with mean age
66.7 ± 13.3 years). CKD etiology in the study group
included: hypertensive and ischemic nephropathy in 32
patients, glomerulonephritis in 5 patients, interstitial
nephritis in 7 patients, polycystic kidney disease in 6
patients, autoimmune disease in 1 patient, whereas
unknown etiology was present in 22 cases. According to
the eGFR levels, patients were divided into four groups,
Group 1 with eGFR levels 89–60 ml/min/1.73 m2 con-
sisted of 21 patients, Group 2 with eGFR levels 59–30 ml/
min/1.73 m2 included 31 patients, Group 3 with eGFR
levels 29–15 ml/min/1.73 m2 consisted of 14 patients, and
Group 4 with eGFR levels\15 ml/min/1.73 m2 consisted
of seven patients. The groups were compared between
regarding all the biochemical variables (Table 1) and
echocardiographic parameters (Table 2).
There were no significant differences between all groups
in age, PLT, MPV, PDW, PCT, and P-LCR. Level of
creatinine, urea, PTH, and NT-proBNP increased in par-
allel with the severity of kidney dysfunction. Hemoglobin,
serum hematocrit, and MCHC were higher in Group 1
compared with groups 3 and 4. RBC level was higher in
Group 1 compared with Group 2 and in Group 2 compared
with Group 3, level of MCV was lower in Group 2 com-
pared with Group 3 and MCH level was higher in Group 1
compared with Group 2. Whereas, level of RDW was
higher in Group 3 compared with groups 1 and 2,
[14.7(13.1–19.5) % vs. 13.6(12.1–14.9) %, p = 0.003 and
Table 2 Standard echocardiography and tissue Doppler echocardiography parameters in four groups of patients according to the eGFR levels
Parameter Group 1 (n = 21) Group 2 (n = 31) Group 3 (n = 14) Group 4 (n = 7) p\ 0.05
LVEDD (cm) 4.3 (3.6–5.8) 4.6 (4.0–6.1) 4.5 (3.7–6.0) 4.8 (4.1–5.6) –
RVEDD (cm) 2.7 (2.1–3.0) 2.7 (2.2–3.3) 2.7 (2.4–3.0) 2.8 (2.2–3.2) –
LAD (cm) 3.9 ± 0.5 4.0 ± 0.5 4.1 ± 0.5 4.2 ± 0.5 –
LVEF (%) 61 (51–61) 60 (50–76) 58 (54–70) 58 (55–71) –
LVMI (g/m2) 80 (62–210) 90 (58–166) 94 (60–198) 100 (98–136) –
IVSDd (cm) 1.0 (0.7–1.4) 1.1 (0.9–1.5) 1.2 (1.0–1.5) 1.2 (1.–1.4) 1–3
LVPWd (cm) 1.0 (0.7–1.5) 1.1 (0.9–1.3) 1.2 (1.0–1.4) 1.2 (1.0–1.3) 1–3
E (cm/s) 68 (53–116) 68 (44–111) 54 (35–93) 63 (38–100) 1–3
A (cm/s) 73 (55–111) 79 (50–118) 80 (58–141) 82 (47–130) –
DecT (msec) 220 ± 46 222 ± 47 253 ± 52 225 ± 71 –
E/A 0.9 (0.6–1.4) 0.9 (0.5–1.6) 0.6 (0.4–0.9) 0.6 (0.4–0.9) 1–3, 2–3
SmLV (cm/s) 8 (6–14) 7 (5–10) 8.5 (6–13) 9 (7–14) 2–4
EmLV (cm/s) 9.0 ± 3.1 8.5 ± 2.3 6.8 ± 2.7 8.0 ± 3.2 –
AmLV (cm/s) 10.2 ± 3.0 9.6 ± 2.0 10.8 ± 2.5 11.3 ± 2.6 –
Em/AmLV 0.9 (0.3–2.1) 0.9 (0.4–2.0) 0.6 (0.4–1.1) 0.5 (0.4–1.8) 1–3, 2–3
E/Em 7.5 (5.5–13.1) 8.8 (4.7–13.8) 8.7 (4.8–14.2) 7.6 (5.2–11.7) –
LVEDD left ventricular end-diastolic dimension, RVEDD right ventricular end-diastolic dimension, LAD left atrial diastolic dimension, LVEF
left ventricular ejection fraction, LVMI left ventricular mass index, IVSDd interventricular septal diastolic diameter, LVPWd left ventricular left
ventricular posterior wall dimension at diastole, E early transmitral peak velocity, A late transmitral peak velocity, DT deceleration time, E/A
ratio of early transmitral peak velocity to late transmitral peak velocity, SmLV peak mitral annular systolic velocity, EmLV peak early diastolic
velocity, AmLV peak late diastolic velocity, Em/AmLV ratio of peak early diastolic velocity to peak late diastolic velocity, E/Em ratio of early
transmitral peak velocity to mitral annular early diastolic velocity, 1 group 1, 2 group 2, 3 group 3, 4 group 4
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vs. 13.7(12.7–16.2) %, p = 0.05], respectively. BMI was
lower in Group 4 compared with Group 2.
Among 73 patients enrolled in our study, we obtained
data on the CRP levels and serum albumin levels of 53
patients only. Patients in Group 3 were characterized by
higher CRP levels than subjects in groups 1 and 2, (4.1
(3.0–36.0) mg/L vs. 2.0 (0.5–6.0) mg/L and vs. 3.0
(1.0–36.0) mg/L), p = 0.005 and p = 0.037), respectively.
Whereas, level of serum albumin did not differ between
four groups. In echocardiographic examination, there were
no significane between all groups in LVEDD, RVEDD,
LAD, LVEF, LVMI, A, DecT, EmLV, AmLV, E/Em ratio.
While, IVSDd and LVPWd were higher in Group 3 com-
pared with Group 1 and E wave was lower in Group 3
compared with Group 1. The ratio of E/A was lower in
Group 3 compared with groups 2 and 1. The ratio of Em/
AmLV determinated by TDI was also lower in Group 3
compared with groups 2 and 1. Additionally, SmLV was
higher in Group 4 compared with Group 2.
To evaluate the RDW level in patients with and without
LVDD (defined as EmLV\ 8 cm/s), patients were divided
into four groups according to the results of EmLV and the
stage of CKD: early stage CKD (eGFR[ 30 ml/min/
1.73 m2) without LVDD (EmLV C 8 cm/s) consisted of
33 subjects, early stage CKD with LVDD (EmLV\ 8 cm/
s) consisted of 16 subjects, advanced stage CKD
(eGFR B 30 ml/min/1.73 m2) without LVDD consisted of
10 subjects, and advanced stage CKD with LVDD with 14
subjects (Tables 3, 4).
Among the biochemical parameters, patients with
advanced stage CKD with and without LVDD as compared
to patients both groups of early stage CKD were
Table 3 Biochemical characteristics of patients from four groups according to the stage of CKD and EmLV
Parameter Early stage CKD
without LVDD (n = 33)
Early stage CKD with
LVDD (n = 16)
Advanced stage CKD
without LVDD (n = 10)
Advanced stage CKD
with LVDD (n = 14)
p\ 0.05
Age (years) 64.4 ± 13.1 69.8 ± 10.3 65.2 ± 13.6 69.5 ± 15.8 –
BMI (kg/m2) 29.1 ± 5.5 29.6 ± 6.2 27.1 ± 3.1 26.7 ± 3.7 –




52 (31–85) 56 (35–79) 16 (10–30) 21 (6–29) 1–3, 1–4,
2–3, 2–4
Urea (mg/dL) 47 (19–74) 44 (29–62) 101 (68–204) 120 (53–163) 1–3, 1–4,
2–3, 2–4
PTH (pg/ml) 48 (24–107) 50 (30–85) 175 (64–408) 157 (66–346) 1–3, 1–4,
2–3, 2–4
NT–proBNP (pg/ml) 96 (12–549) 191 (35–643) 520 (65–966) 518 (46–4,968) 1–3, 1–4,
2–4
Hb (g/dL) 13.4 ± 1.3 13.5 ± 1.7 10.6 ± 1.6 12.0 ± 1.8 1–3, 2–3,
2–4
HT (%) 39 (13–46) 41 (13–49) 35 (26–38) 36 (13–43) 1–3, 2–3
PLT (103/uL) 225 (66–453) 219 (45–334) 208 (150–287) 180 (127–484) –
RBC (106/uL) 4.5 ± 0.5 4.5 ± 0.6 3.6 ± 0.5 4.0 ± 0.6 1–3, 2–3
MCV (fL) 89.6 ± 4.5 90.0 ± 4.0 92.2 ± 5.3 91.1 ± 6.9 –
MCH (pg) 30.2 ± 1.7 30.3 ± 1.1 30.1 ± 1.3 30.1 ± 2.8 –
MCHC (g/dL) 34 (32–37) 34 (33–36) 33 (30–35) 33 (30–35) 2–4
RDW (%) 13.7 (12.1–16.2) 13.8 (13.1–14.9) 13.7 (11.4–15.4) 14.5 (13.8–19.5) 1–4, 2–4,
3–4
MPV (fL) 11.0 ± 1.0 11.0 ± 1.1 11.1 ± 0.7 11.6 ± 1.4 –
PDW (fL) 13.6 (9.5–20.1) 13.0 (10.4–16.7) 13.4 (11.6–23.6) 13.6 (11.6–23.6) –
PCT (%) 0.24 (0.07–0.44) 0.25 (0.06–0.37) 0.25 (0.18–0.31) 0.23 (0.15–0.50) –
P-LCR (%) 33.2 ± 8.2 33.3 ± 8.3 33.7 ± 5.7 38.0 ± 11.0 –
CRP (mg/L) 2.0 (0.5–30.0) 2.6 (1.6–36.0) 3.1 (1.0–19.0) 6.0 (1.0–36.0) 1–4
Albumin (g/dL) 3.82 (3.22–4.60) 3.98 (3.30–4.58) 3.88 (2.62–4.12) 3.77 (2.75–4.68) –
CKD chronic kidney disease, LVDD left ventricular diastolic dysfunction, BMI body mass index, eGFR estimated glomerular filtration rate, PTH
parathormone, NT-proBNP N-terminal pro brain natriuretic peptide, Hb hemoglobin concentration, HT hematocrit, PLT platelets, RBC red blood
cells, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration, RDW red cell
distribution width, MPV mean platelet volume, PDW platelet distribution width, PCT plateletcrit, P-LCR platelet-large cell ratio, CRP C-reactive
protein, 1 Early stage CKD without LVDD, 2 Early stage CKD with LVDD, 3 Advanced stage CKD without LVDD, 4 Advanced stage CKD
with LVDD
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characterized by significantly higher level of creatinine,
urea, PTH, and by significantly lower eGFR levels. NT-
proBNP level was higher in advanced stage CKD with
LVDD group compared with early stage CKD group with
and without LVDD, and was higher in group with
advanced CKD without LVDD than group with early stage
CKD without LVDD. Whereas, NT-proBNP level did not
differ between groups with and without LVDD in both
groups of early and advanced CKD. Hemoglobin, serum
hematocrit, and RBC were lower in advanced stage CKD
without LVDD compared with both groups of early stage
CKD. Additionally, hemoglobin was lower in advanced
stage CKD with LVDD compared with early stage CKD
with LVDD. MCHC level was lower in advanced stage
CKD with LVDD compared with early stage CKD with
LVDD, while CRP level was higher in advanced stage
CKD with LVDD compared with early stage CKD without
LVDD.
Patients with advanced stage CKD with LVDD as
compared with advanced stage CKD without LVDD were
characterized by significantly higher level of RDW [14.5
(13.8–19.5) vs. 13.7 (11.4–15.4) %, p = 0.049], respec-
tively. Additionally, level of RDW was higher in
advanced stage CKD with LVDD compared with both
groups of early stage CKD. There were no significant
differences between all groups in age, BMI and levels of
PLT, MCV, MCH, MPV, PDW, PCT, P-LCR, and
albumin.
Table 4 Standard echocardiography and tissue Doppler echocardiography parameters in four groups of patients according to the stage of CKD
and EmLV
parameter Early stage CKD without
LVDD (n = 33)
Early stage CKD with
LVDD (n = 16)
Advanced stage CKD without
LVDD (n = 10)
Advanced stage CKD with




4.5 ± 0.5 4.8 ± 0.7 4.6 ± 0.3 4.7 ± 0.7 –
RVEDD
(cm)
2.7 (2.1–3.0) 2.8 (2.3–3.3) 2.7 (2.3–3.0) 2.8 (2.2–3.2) 1–2
LAD
(cm)
3.9 ± 0.5 4.2 ± 0.5 4.0 ± 0.3 4.2 ± 0.6 –
LVEF
(%)
63 (51–76) 59 (50–66) 58 (54–69) 58 (54–71) 1–2, 1–3
LVMI (g/
m2)
83 (58–138) 107 (74–210) 97 (81–127) 99 (60–198) 1–2
IVSDd
(cm)
1.0 (0.7–1.5) 1.15 (1.0–1.3) 1.1 (0.9–1.4) 1.2 (1.0–1.5) 1–2, 1–4
LVPWd
(cm)
1.0 (0.7–1.3) 1.2 (0.9–1.5) 1.1 (1.0–1.3) 1.2 (1.0–1.4) 1–2, 1–4
E (cm/s) 73 ± 17 59 ± 12 70 ± 15 54 ± 17 1–2, 1–4
A (cm/s) 71 (54–105) 79 (63–111) 79 (47–118) 80 (55–141) –
DecT
(msec)
217 ± 41 230 ± 56 222 ± 52 255 ± 60 –
E/A 0.94 (0.65–1.42) 0.70 (0.53–1.17) 0.84 (0.56–1.65) 0.60 (0.42–1.24) 1–2, 1.4
SmLV
(cm/s)
8 (5–14) 7 (6–9) 9 (7–13) 7 (6–14) 1–2, 2–3
EmLV
(cm/s)




9 (7–17) 10 (6–13) 12 (6–16) 10 (7–14) –
Em/
AmLV
1.0 (0.5–2.1) 0.55 (0.33–1.16) 0.88 (0.56–2.0) 0.50 (0.37–0.77) 1–2, 1–4,
3–4
E/Em 7.4 (4.7–11.2) 9.7 (6.9–13.8) 6.1 (4.8–11.6) 9.1 (6.2–14.3) 1–2, 2–3
CKD chronic kidney disease, LVDD left ventricular diastolic dysfunction, LVEDD left ventricular end-diastolic dimension, RVEDD right
ventricular end-diastolic dimension, LAD left atrial diastolic dimension, LVEF left ventricular ejection fraction, LVMI left ventricular mass
index, IVSDd interventricular septal diastolic diameter, LVPWd left ventricular left ventricular posterior wall dimension at diastole, E early
transmitral peak velocity, A late transmitral peak velocity, DT deceleration time, E/A ratio of early transmitral peak velocity to late transmitral
peak velocity, SmLV peak mitral annular systolic velocity, EmLV peak early diastolic velocity, AmLV peak late diastolic velocity, Em/AmLV ratio
of peak early diastolic velocity to peak late diastolic velocity, E/Em ratio of early transmitral peak velocity to mitral annular early diastolic
velocity, 1 Early stage CKD without LVDD, 2 Early stage CKD with LVDD, 3 Advanced stage CKD without LVDD, 4 Advanced stage CKD
with LVDD
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At echocardiography, patients with early stage CKD
without LVDD compared with early and advanced stage
CKD with LVDD were characterized by significantly lower
level of IVSDd and LVPWd and higher level of E wave
and ratio of E/A. Additionally, patients with early stage
CKD without LVDD compared with early stage CKD with
LVDD were characterized by higher levels of LVEF,
SmLV, EmLV, Em/AmLV ratio and lower levels of
RVEDD, LVMI, E/Em ratio. Additionally, subjects with
advanced stage CKD with LVDD were characterized by
lower levels of EmLV and Em/AmLV ratio than subjects
with advanced stage CKD without LVDD. While, the
levels of E/A ratio and E/Em ratio did not differ between
both groups of advanced stage CKD. There were no sig-
nificant differences between all groups in LVEDD, LAD, A
wave, DecT of E wave, and AmLV.
ROC analysis
The area under the ROC curve of RDW level for the
detection of LVDD was 0.649, 95 % CI (0.528–0.758),
p = 0.021. The optimal cut-off value in the ROC analysis
for RDW was [13.5 %. This value was characterized by
the sensitivity of 83.3 % for diagnosing LVDD and spec-
ificity of 45.2 %; positive predictive value (PPV) was 52 %
and negative predictive value (NPV) was 79 % (Fig. 1).
The area under the ROC curve of NT-proBNP level for
the detection of LVDD was 0.685, 95 %CI (0.563–0.791),
p = 0.006. The optimal cut-off value in the ROC analysis
for RDW was[171.2 pg/ml. This value was characterized
by the sensitivity of 75.0 % and specificity of 66.7 % for
diagnosing LVDD; PPV was 60 % and NPV was 80 %
(Fig. 2).
There was also no significant differences for diagnostic
accuracy between the two methods (p = 0.755).
Correlation analysis
We investigated the correlations of RDW with laboratory
and echocardiographic parameters that determine LVDD.
RDW level was significantly correlated with log NT-
proBNP (r = 0.447, p = 0.0001) (Fig. 3). We obtained
also significant negative correlation between RDW level
with level of eGFR (r = -0.385, p = 0.0008) (Fig. 4).
Additionally, we performed the correlation between level
of EmLV and following parameters: BMI, level of CRP,
albumin, NT-proBNP, RDW (Table 5). Among these
parameters, we obtained significant negative correlations
between EmLV and CRP, NT-proBNP and RDW levels.
Furthermore, we did not obtain the relationship between
the antihypertensive treatment with use of inhibitors of
rennin-angiotensin system and LVDD, p = 0.386.
Fig. 1 Receiver operating characteristic curves for RDW to predict
LV diastolic dysfunction
Fig. 2 Receiver operating characteristic curves for NT-proBNP to
predict LV diastolic dysfunction
Fig. 3 Positive correlation between RDW level and logNT-proBNP
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Univariate and multivariate logistic regression
To determine the diagnostic value of laboratory parame-
ters, univariate logistic regression analysis was performed
and odds radio was calculated. Using stepwise regression,
we created a model useful for the diagnosis of LVDD in
CKD patients.
Only those parameters with p\ 0.1 in univariate
logistic regression were considered in multivariable ana-
lysis (Table 6).
Among the examined biochemical parameters, only an
increased RDW level was found to be an independent
predictive factor for LVDD. Other parameters did not reach
statistical significance in multivariate analysis.
Discussion
Many previous studies have shown that the increased value
of RDW level is associated with a worse prognosis for
patients with acute (AHF) and chronic heart failure (CHF),
with previous myocardial infarcts or strokes [6–10, 19]. Al-
Najjar et al. [6] showed that the level of the RDW is
important in determining the prognosis among patients
with CHF and its prognostic strength is comparable to NT-
proBNP levels. The study of Fo¨rhe´cz Z et al. [20] found,
however, that the strength of the RDW prognostic in
patients with CHF is even greater than the concentration of
NT-proBNP. The results of a single study indicate that the
RDW is an independent factor of death in patients with
pulmonary hypertension and also showed that RDW is
statistically stronger and more important than NT-proBNP
[11]. In our study, among all laboratory parameters,
patients with advanced stage CKD with LVDD compared
with patients with advanced stage CKD without LVDD had
significantly higher concentrations of RDW level only.
Whereas, the level of RDW was not significantly different
between early stage CKD patients with and without LVDD.
Therefore, the sensitive predict factor for RDW for prog-
nosis LVDD was dependent on the CKD stage.
Importantly, we observed higher RDW levels in patients
with eGFR levels \30 ml/min/1.73 m2 compared with
patients with eGFR C30 ml/min/1.73 m2, and RDW
showed significant negative correlation with eGFR in the
studied groups. Additionally, an increased RDW levels can
be a novel factor for diagnosis LVDD in this group of
patients. Among the examined laboratory factors, the RDW
was the strongest prognostic, even more powerful than the
NT-proBNP.
However, in the logistic regression analysis, only the
RDW was an independent risk factor of diastolic dys-
function among patients with CKD. Other authors showed
that the RDW correlated well with ratio of E/Em and NT-
proBNP. A value of RDW[ 13.6 % and NT-proB-
NP[ 125 pg/ml has high diagnostic accuracy for pre-
dicting DHF [13]. In the study of Oh J et al. [21], they
found another cut-off value of RDW for predicting
E/Em[ 15. The value was 13.45 %. In our study, the
value of RDW[ 13.5 % obtained a good diagnostic value
of LV diastolic dysfunction. In another study Solak Y et al.
[12], presented the RDW as an independent predictor for
endothelial dysfunction in patients with CKD. The mech-
anisms underlying these relationships remain unclear,
although several explanations have been proposed. A direct
effect of changes in erythrocyte function on the heart seems
plausible, as erythrocytes both carry oxygen to tissues and
organs and have an important role in cardiovascular regu-
lation through release of extracellular nucleotides and other
mediators [22]. This suggests that the cardiovascular
autonomic function could be impaired in patients with high
RDW levels. Additionally, an increased RDW level in
patients with CHF would be associated with an inflam-
mation. The persistent inflammation is known to be a
principal pathophysiologic finding for endothelial dys-
function and heart failure [23, 24]. It has also been sug-
gested that RDW could be a marker of oxidative stress
[25], which could be associated with LVDD.
Fig. 4 Negative correlation between RDW level and eGFR level
Table 5 Correlation between
EmLV levels and other factors
EmLV peak early diastolic
velocity, r Spearman
correlation, BMI body mass
index, CRP C-reactive protein,
NT-proBNP N-terminal pro
brain natriuretic peptide, RDW




BMI (kg/m2) -0.124 0.293







RDW (%) -0.234 0.047
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The results of our study are similar to the results of
studies available in the literature [13, 21]. They confirm the
usefulness of the RDW levels in determining diastolic
dysfunction also among patients with CKD. These reports
are very important especially when you consider the fact
that the RDW is a parameter widely available to clinicians
as a result of the morphology of the blood component. The
determination of the level of RDW is therefore not asso-
ciated with additional costs, in contrast to other new
diagnostic factors, of which determination is relatively
expensive and not always available. The pathophysiologi-
cal mechanisms are still unclear underlying dependence
elevated levels of RDW and LVDD. Therefore, further
studies evaluating the LVDD are needed.
There are potential limitations of this study. Firstly, a
relatively small, one-center study group. Secondly, we
assessed the CRP and serum albumin levels only of 53
patients among of 73 patients enrolled in the our study.
Thirdly, we did not measure vitamin B12 and foliate levels,
and another proinflammatory levels of cytokines, which are
one of the potential causes of increased levels of RDW.
Fourthly, the lack of blood pressure in our patients.
Conclusion
RDW values were increased in patients with LVDD in the
advanced stage CKD population. Our results suggest that
high RDW may be related to LVDD in this group of patients.
RDW can be used as an additional factor for the diagnosis of
LVDD in patients with advanced stage of CKD.
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Table 6 Biochemical parameters for the prediction of LV diastolic dysfunction (EmLV\ 8 cm/s). Univariate and multivariate logistic
regression analysis
Parameter Univariate analysis Multivariate analysis
OR 95 % CI p OR 95 % CI p
Creatinine (mg/dL) 1.46 0.93–2.30 0.093 1.19 0.35–4.04 0.777
eGFR (ml/min/1.73 m2) 0.98 0.96–1.00 0.158
Urea (mg/dL) 1.01 0.99–1.02 0.050 1.01 0.98–1.03 0.648
Log PTH (pg/ml) 3.62 0.71–18.39 0.114 0.39 0.02–7.61 0.527
Log NT-proBNP (pg/ml) 4.56 1.43–14.55 0.009 3.38 0.73–15.68 0.113
Hb (g/dL) 1.01 0.78–1.31 0.908
HT (%) 0.98 0.92–1.04 0.564
Log PLT (103/uL) 0.25 0.01–5.25 0.368
RBC (106/uL) 0.96 0.43–2.13 0.933
MCV (fL) 1.02 0.93–1.12 0.591
MCH (pg) 1.03 0.78–1.33 0.836
MCHC (g/dL) 0.90 0.59–1.36 0.621
RDW[ 13.5 % 4.13 1.30–13.13 0.014 3.92 1.05–14.56 0.037
MPV (fL) 1.28 0.81–2.01 0.284
PDW (fL) 1.14 0.94–1.37 0.180
PCT (%) 0.22 0.00–126.9 0.631
P-LCR (%) 1.03 0.97–1.09 0.313
CRP (mg/L) 1.06 0.97–1.15 0.169
Albumin (g/dL) 0.88 0.24–3.17 0.840
OR odds ratio, CI confidence interval, eGFR estimated glomerular filtration rate, Hb hemoglobin concentration, HT hematocrit, log NT-proBNP
logarithm of N-terminal pro brain natriuretic peptide, log PLT logarithm of platelets, log PTH logarithm of parathormone, MCH mean
corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration, MCV mean corpuscular volume, MPV mean platelet volume, OR
odds ratio, PCT plateletcrit, PDW platelet distribution width, P-LCR platelet-large cell ratio, RBC red blood cells, RDW red cell distribution
width, CRP C-reactive protein
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